300-million child antimalarial treatments supplied

Novartis (NVS) announced today that it has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries. CoartemĀ® Dispersible is the first artemisinin-combination therapy (ACT) developed by Novartis in collaboration with Medicines for Malaria Venture (MMV) […]